Sign In
Buy DFFN
$5.87
+0 (+0%)
At Close: Nov 28, 2023
CervoMed Announces Completion of Merger with EIP Pharma
01:58pm, Wednesday, 16'th Aug 2023
Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
04:01pm, Tuesday, 15'th Aug 2023
Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5 Reverse Stock Split Merger on Track to Close on August 16, 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN
02:13pm, Monday, 03'rd Apr 2023
NEW YORK , April 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Diffusion
DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders
10:42am, Thursday, 30'th Mar 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) and EIP Pharma Inc. is fair to Diffusion
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
09:01pm, Monday, 14'th Nov 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies t
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
11:30am, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
10:30am, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
02:12pm, Tuesday, 16'th Aug 2022 Benzinga
Upgrades
Craig-Hallum upgraded the previous rating for CalAmp Corp (NASDAQ:CAMP) from Hold to Buy. In the first quarter, CalAmp showed an EPS of $0.10, compared to $0.08 from the year-ago quarter. At
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
10:48pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cas
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
11:30am, Thursday, 23'rd Jun 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that en
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
07:30am, Tuesday, 17'th May 2022
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
11:20am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies th
5 Stocks Halted In Tuesday's Session
06:01pm, Tuesday, 19'th Apr 2022
A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to
Diffusion Pharmaceuticals (DFFN) Stock: 1-For-50 Reverse Stock Split Announced
08:28pm, Monday, 18'th Apr 2022
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced it will effect a 1-for-50 reverse stock split of its common stock. These are the details.
